Adipokines in Hemodialysis Patients
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 9/23/2012 |
| Start Date: | May 2008 |
| End Date: | June 2013 |
| Contact: | Srinivasan Beddhu, M.D. |
| Email: | srinivasan.beddhu@hsc.utah.edu |
| Phone: | 801-585-3810 |
This is a double blinded RCT of pioglitazone vs. placebo in overweight or obese, diabetic
and non-diabetic hemodialysis patients. This study will examine whether pioglitazone
modulates adipokine production by adipose tissue in hemodialysis patients and whether these
changes result in reduction of inflammation, insulin resistance and oxidative stress and
increase in muscle mass.
In addition, this study will also examine the associations of adiposity with adipokines and
the metabolic milieu in hemodialysis patients to better understand the biology of adipocytes
in uremic milieu.
Inclusion Criteria:
- Overweight (BMI ≥ 25 kg/m2)
- Adult
- Chronic hemodialysis
- Diabetic (type 2) or insulin resistant
Exclusion Criteria:
- <18 years old
- No insulin resistance
- Active liver disease
- Class III or IV New York Heart Association heart failure
- Macular edema or hard exudates near macula on fundoscopy
- Current active malignancy (excluding squamous and basal cell skin cancers)
- Active AIDS
- Chronic lung disease requiring supplemental oxygen therapy
- Enrolled in interventional trials using drugs or devices
- Bone break of long bones, vertebrae, or hips in the past three years
We found this trial at
2
sites
University of Utah Research is a major component in the life of the U benefiting...
Click here to add this to my saved trials
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials